Sisätautien yksikkö
Department of Internal Medicine

Julkaisut 2005
Publications 2005

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Pajunen P et al. Five-year risk of developing clinical diabetes after first myocardial infarction; the FINAMI study.
2 Dormandy JA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
3 Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what about the beta-cell and the mitochondria? Response to Eldor and Raz.
4 Dahlman I et al. The CIDEA gene V115F polymorphism is associated with obesity in Swedish subjects.
5 Erkkilä AT et al. Antibodies against oxidized LDL and cardiolipin and mortality in patients with coronary heart disease.
6 Esapa C et al. Islet amyloid polypeptide gene promoter polymorphisms are not associated with type 2 diabetes or with the severity of islet amyloidosis.
7 Fröjdö S et al. Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy.
8 Fueger PT et al. Hexokinase II protein content is a determinant of exercise endurance capacity in the mouse.
9 González-Sánchez JL et al. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance.
10 Hakala T et al. Right atrial overdrive pacing does not prevent atrial fibrillation after coronary artery bypass surgery.
11 Halinen M. Sydänsairaudet ja moottoriajoneuvon kuljettaminen.
12 Halinen M et al. Sydänperäinen aivoembolisaatio.
13 Halinen MO. Kohtauksittainen eteisvärinä: milloin tarvitaan antikoagulaatiohoitoa?
14 Hannonen P. Mikä hoidoksi fibromyalgiaan?
15 Hannuksela J et al. Hereditary hemochromatosis gene (HFE) mutations C282Y, H63D and S65C in patients with idiopathic dilated cardiomyopathy.
16 Hartikainen J. Rytmihäiriöiden muuttuva hoito.
17 Heikkinen M et al. Removing a biliary T-tube and retained stone by ERCP. A case report.
18 Heikkinen M et al. Clinical value of ultrasound in the evaluation of dyspepsia in primary health care.
19 Heinonen S et al. Associations between two single nucleotide polymorphism in the adiponectin gene and polycystic ovary syndrome.
20 Hintikka J, Niskanen L. Skitsofrenia lisää diabeteksen ja sydän-ja verisuonisairauksien vaaraa. Ehkäisyyn on panostettava.
21 Huopio H et al. Synnynnäinen hyperinsulinismi.
22 Häkkinen A et al. Pain and joint mobility explain individual subdimensions of the health assessment questionnaire (HAQ) disability index in patients with rheumatoid arthritis.
23 Häkkinen A et al. Decreased muscle strength and mobility of the neck in patients with rheumatoid arthritis and atlantoaxial disorders.
24 Häkkinen A et al. Effects of prolonged combined strenght and endurance training on physical fitness, body composition and serum hormones in women with rheumatoid arthritis and in healthy controls.
25 Ikäheimo R et al. Discontinuation of dialysis treatment: Experience of a single dialysis centre.
26 Jantunen E et al. Autologous stem cell transplantation in patients with high-risk plasmacytoma.
27 Jantunen E, Luosujärvi R. Stem cell transplantation in autoimmune diseases: an uptake.
28 Jantunen E, Vornanen M. Perifeeriset T-solulymfoomat.
29 Juutilainen A. Gender, Type 2 Diabetes and Risk of Cardiovascular Disease.
30 Juutilainen A et al. Type 2 diabetes as a "coronary heart diasease equivalent". An 18-year prospective population-based study in Finnish subjects.
31 Juutilainen AM et al. Plasma aldosterone to renin ratio predicts treatment response in primary aldosteronism: is volume loading needed?
32 Kattainen A et al. Coronary heart disease: from a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s.
33 Kattainen A et al. Gender differences in the treatment and secondary prevention of CHD at population level.
34 Kauppi M et al. Survey nonresponse is associated with increased mortality in patients with rheumatoid arthritis and in a community population.
35 Kauppinen-Mäkelin R et al. A nationwide survey of mortality in acromegaly.
36 Kemppainen T et al. Elevated expression of hyaluronan and its CD44 receptor in the duodenall mucosa of coeliac patients.
37 Kilhovd BK et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men. A population-based 18-year follow-up study.
38 Kivelä A, Hartikainen J. Restenoosi pallolaajennuksen jälkeen - ongelma ratkeamassa.
39 Koivisto TT et al. First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens.
40 Korpela M, Hannonen P. Miten perinteisiä reumalääkkeitä pitäisi käyttää nivelreuman hoidossa?
41 Korytkowski M et al. FlexPen (R): Addressing issues of confidence and concenience in insulin delivery.
42 Krishnan E et al. Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis.
43 Kuittinen T et al. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
44 Kuittinen T et al. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey.
45 Kurl S et al. Cardiac power during exercise and the risk of stroke in men.
46 Kuuliala A et al. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
47 Kuusisto J. Sydämen vajaatoiminta - monimuotoinen haaste.
48 Kuusisto J et al. Atherosclerosis-like lesions of the aortic valve are common in adults of all ages: a necropsy study.
49 Laakso M. Prevention of type 2 diabetes.
50 Laakso M. Metabolisen oireyhtymän uudet kriteerit ja hoito.
51 Laakso M, Kuusisto J. Insulin resistance and coronary heart disease.
52 Laaksonen DE et al. Physical activity in the prevention of type 2 diabetes. The Finnish diabetes prevention study.
53 Laaksonen DE et al. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study.
54 Laaksonen DE et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study.
55 Laaksonen DE et al. Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids.
56 Laaksonen DE et al. Dietary carbohydrate modification enchances insulin secretion in persons with the metabolic syndrome1-3.
57 Laukkanen O et al. Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversation from impaired glucose tolerance to type 2 diabetes.The Finnish diabetes prevention study.
58 Lehto M et al. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience.
59 Luoma JS et al. Autoantibodies against oxidized LDL are associated with severe chest pain attacks in patients with coronary heart disease.
60 Malmberg K et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI ): effects on mortality and morbidity.
61 Mousavinasab F et al. Common polymorphisms in the PPARgamma2 and IRS-1 genes and their interaction influence serum adiponectin concentration in young Finnish men.
62 Mousavinasab F et al. Effect of the Pro12Ala polymorphism of the PPARgamma2 gene on serum adiponectin changes.
63 Mäkinen H et al. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. A 5-year followup study.
64 Mäkinen H et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arhtritis?
65 Mäntyselkä P et al. Väestökyselyn tulokset lääkäripalvelujen käytöstä. Lääkäripalvelujen laatu Suomessa 2004-tutkimus.
66 Pajala M et al. Mental distress in patients with functional or organic dyspepsia: a comparative study with a sample of the general population.
67 Pajala M et al. Comment on [Abdominal complaints in general practise: diagnoses and characteristics of patients].
68 Pajunen P et al. Sydäninfarktidiagnoosin luotettavuus hoitoilmoitus- ja kuomensyyrekisterissä vuosina 1988-2005.
69 Pajunen P et al. The validity of the Finnish hospital discharge register and causes of death register data on coronary heart disease.
70 Pajunen P et al. Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study.
71 Pedersen TR et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: A randomized controlled trial.
72 Peltola P et al. Genetics and phenotypic characteristics of autosomal dominant polycystic kidney disease in Finns.
73 Penttilä K. Evaluation of Different Biochemical Methods to Detect Myocardial Injury.
74 Pihlajamäki J et al. Haplotypes of PPARGC1A are associated with glucose tolerance, body mass index and insulin sensitivity in offpring of patients with type 2 diabetes.
75 Puolakka K et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis. Five-year experience from the FIN-RACO Trial.
76 Puolakka K et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study.
77 Pätäri A et al. A 100-kDa urinary protein is associated with insulin resistance in offspring of type 2 diabetic patients.
78 Raatikainen MJP et al. Microvolt T-wave alternans during exercise and pacing in patients with acute myocardial infarction.
79 Roden M et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with type 2 diabetes mellitus.
80 Saarela T et al. Tumour necrosis factor-alpha gene haplotype is associated with pre-eclampsia.
81 Saarelainen J et al. Cross-calibration of lunar DPX-IQ and DPX dual-energy X-ray densitometers for bone mineral measurements in women.
82 Salmenniemi U et al. High amount of visceral fat mass is associated with multiple metabolic changes in offspring of type 2 diabetic patients.
83 Salmenniemi U et al. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure, and cytokines in offspring of type 2 diabetic patients.
84 Salomaa V et al. A new definition for myocardial infarction: what difference does it make?
85 Salopuro T et al. Genetic variation in leptin receptor gene is associated with type 2 diabetes and body weight: The Finnish diabetes prevention study.
86 Sane T et al. Insuliinipumppu tyypin 1 aikuisdiabeetikoiden hoitona.
87 Saraheimo M et al. Serum adiponectin in increased in type 1 diabetic patients with nephropathy.
88 Saraheimo M et al. Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy.
89 Siirilä-Waris K et al. Akuutti sydämen vajaatoiminta Suomessa monikeskustutkimuksen valossa.
90 Sipola P et al. Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asp175Asn mutation in the alpha-tropomyosin gene.
91 Suomen Kardiologisen seuran asettama työryhmä. Eteisvärinä. Käypä hoito -suositus.
92 Tapola N et al. Glycemic responses of oat bran products in type 2 diabetic patients.
93 Tarkiainen TH et al. Stability over time of short-term heart rate variability.
94 The DECODE Study Group. Comparison of three different definitions for the metabolic syndrome in non-diabetic Europeans. The DECODE Study Group.
95 The Field study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
96 The FIELD Study Investigators. Fenofibrate intervention and event lowering in diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481] .
97 Thron LM et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study).
98 Timonen T et al. Gaucherin tauti.
99 Tuomainen P et al. Warm-up phenomenon and cardiac autonomic control in patients with coronary artery disease.
100 Tuomainen P et al. Regular physical exercise, heart rate variability and turbulence in a 6-year randomized controlled trial in middle-aged men: the DNASCO study.
101 Udd M et al. The effect of regular and high doses of omeprazole on the intragastric acidity in patients with bleeding peptic ulcer treated endoscopically: a clinical trial with continuous intragastric pH monitoring.
102 Valkamo M et al. Sepelvaltimotautipotilaan masennuksen diagnostiikkaa ja hoito.
103 Valkeinen H et al. Muscle hypertrophy, strength development, and serum hormones during strength training in elderly women with fibromyalgia.
104 Van Gaal LF et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
105 Vauhkonen I et al. Subtle hyperproinsulinaemia characterises the defective insulin secretory capacity in offspring of glutamic acid decarboxylase antibody-positive patients with latent autoimmune diabetes mellitus in adults.
106 Viinamäki H et al. Hamiltonin asteikko masennuksen seurannassa käyttökelpoinen yleislääkärin työkalu.
107 Vikman S et al. Sepelvaltimotautikohtauksen hoito Suomessa.
108 Vänttinen M et al. Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene are associated with skeletal muscle glucose uptake.
109 Vänttinen M et al. The effect of the Ala12 allele of the peroxisome proliferator-activated receptor-gamma2 gene on skeletal muscle glucose uptake depends on obesity: a positron emission tomography study.
110 Yang X et al. Effect of the interleukin-6 (-174) G/C promoter polymorphism on adiponectin and insulin sensitivity.
111 Zacharova J et al. Leptin receptor gene variation predicts weight change in subjects with impaired glucose tolerance.
112 Zacharova J et al. The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: The STOPP-NIDDM trial.
113 Zacharova J et al. The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.

Sisätautien yksikkö Department of Internal Medicine
Julkaisutietokanta 15.4.2008 Publications Data Base 15.4.2008